This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

EU Pharmaceutical Law Forum
EU Pharmaceutical Law Forum 2025
20-22 May, 2025Steigenberger Wiltcher's, Brussels

Laetitia Szaller
General Counsel & Head of Compliance at Egetis Therapeutics AB
Speaker

Profile

General Counsel | Strategic Advisor | Life Science Expert

Laetitia brings over two decades of diverse experience spanning various industries, with a commendable 17 years dedicated to the pharmaceuticals and medical device sector. Her expertise extends to steering and overseeing intricate multi-jurisdictional operations, including the orchestration of global multimillion-dollar M&A transactions, licensing agreements, and collaborative partnerships.

In her current role at Egetis Therapeutics, where she assumed responsibilities in December 2023, Laetitia manages the global legal and compliance functions. Prior to this, she played a pivotal role in the Legal operations and Corporate Development at AM-Pharma. Her professional journey also includes significant contributions at UCB as the global Associate General Counsel for BD, M&A, and Antitrust, as well as the Legal Director for Emerging Markets EMEA, Central European Region, and Benelux at Zoetis (formerly Pfizer's animal health division). Laetitia has also spearheaded the EMEA legal department for the Abbott Vascular division at Abbott. Beyond the healthcare realm, she held notable global positions at the Carlson Rezidor Hotel Group and in the automotive division (Wabco) at American Standard.

Laetitia holds qualifications as a lawyer in both the UK and Belgium, showcasing her extensive international experience. Renowned for her insights, she is a regular speaker at various legal conferences, contributing her wealth of knowledge and expertise to the legal community.

Agenda Sessions

  • Opening Remarks from Chair

    08:50
  • DUAL DIALOGUE Key Aspects of IP and How to Avoid Litigation in Deals

    14:10